Immunovia - Discover and develop tools for early diagnosis of cancers

Immunovia walk around the world to raise awareness for pancreatic cancer
July – November 2020

Welcome to join us!

Click to register

Immunovia leads clinical validation studies with > 10,000 subjects recruited at 24 sites from Europe and USA covering the three highest risk groups for pancreatic cancer

Designed to validate IMMray™ PanCan-d, PanFAM-1 is the largest prospective multicenter clinical study for early detection of pancreatic cancer in familial high risk individuals

Immunovia initiated PanDIA-1, the world’s largest study for early detection of pancreatic cancer in the high risk group of new onset diabetic patients

IMMray™ PanCan-d is undergoing evaluation study for diagnosing high risk early symptomatic patients at a treatable stage of pancreatic cancer

IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective studies with 1800 samples

Breakthrough in autoimmune testing – IMMray™ based novel biomarker signature identifies patients with anti-CCP negative rheumatoid arthritis

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

MOVIE
Immunovia and
IMMray™ technology
(10 min)

Press releases

September 2, 2020

Immunovia Announces Management Team Changes

August 31, 2020

NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB

August 28, 2020

Registration Details for Immunovia’s Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities

Financial reports

August 2020

Immunovia AB published the company’s Interim Report Jan-June 2020 on Thursday, August 20, 2020, at 16.00 p.m. CET.

Imunovia Interim Report Jan-June 2020 (PDF in English)

Immunovia Interim Report Jan-June 2020 (PDF in Swedish)

Financial reports

Calendar

22-23 September, 2020

Pri-Med Atlanta, Primary Care CME/CE

Place: Atlanta, GA, USA

1-3 October, 2020

RCGP Annual Primary Care Conference and Exhibition – Postponed to February 2021

Place: Glasgow, UK

28-31 October, 2020

APA 2020 Annual Meeting, American Pancreatic Association

Place: Miami, FL, USA